Cingulate (CING) Payables (2021 - 2026)
Cingulate's (CING) quarterly Payables came in at $8.3 million in Q4 2025, up 119.4% YoY from $3.8 million in Q4 2024, and up 105.67% on a QoQ basis from $4.1 million in Q3 2025.
Cingulate (CING) Payables (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Payables data on file, last reported at $8.3 million in Q4 2025.
- Quarterly Payables rose 119.4% year-over-year to $8.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.3 million (up 119.4% YoY) and the FY2025 annual result came in at $8.3 million, up 119.4% from the prior year.
- Payables rose to $8.3 million in Q4 2025, from $4.1 million in the prior quarter.
- In the past five years, Payables ranged from a high of $9.6 million in Q2 2023 to a low of $264687.0 in Q4 2021.
- A 5-year average of $4.0 million and a median of $4.4 million in 2023 frame the typical range for Payables.
- Annual changes were most pronounced in 2023 — Payables jumped 3305.39% — and 2024, when it tumbled 86.82%.
- Tracing CING's Payables over 5 years: stood at $264687.0 in 2021, then soared by 2077.05% to $5.8 million in 2022, then surged by 42.29% to $8.2 million in 2023, then slumped by 53.69% to $3.8 million in 2024, then soared by 119.4% to $8.3 million in 2025.
- The last three Payables figures came in at $8.3 million (Q4 2025), $4.1 million (Q3 2025), and $5.0 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | 7.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.05 Mn |
| Dec 31, 2025 | 8.33 Mn |
| Sep 30, 2025 | 4.05 Mn |
| Mar 31, 2025 | 4.98 Mn |
| Dec 31, 2024 | 3.80 Mn |
| Sep 30, 2024 | 906,215.00 |
| Jun 30, 2024 | 1.33 Mn |
| Mar 31, 2024 | 737,949.00 |
| Dec 31, 2023 | 8.20 Mn |
| Sep 30, 2023 | 4.67 Mn |
| Jun 30, 2023 | 9.61 Mn |
| Mar 31, 2023 | 5.60 Mn |
| Dec 31, 2022 | 5.76 Mn |
| Sep 30, 2022 | 5.39 Mn |
| Jun 30, 2022 | 282,265.00 |
| Mar 31, 2022 | 556,326.00 |
| Dec 31, 2021 | 264,687.00 |